IOBT | tickerfilter.com

Fundamental analysis

28%

Profitability 0%

Dept financing 29%

Liquidity 50%

Performance 50%

Company vs Stock growth

N/A

1.530 0.927

-0.603 -39.39%

+ Add row to compare

Performance

5 Days

-15.44%

1 Month

-3.15%

3 Months

-4.45%

6 Months

-24.35%

1 Year

-48.31%

2 Year

-55.50%

Key data

Stock price

$0.83

P/E Ratio

0.00

DAY RANGE

$0.83 - $0.96

EPS

-$0.97

52 WEEK RANGE

$0.66 - $1.79

52 WEEK CHANGE

-$47.33

MARKET CAP

69.175 M

YIELD

N/A

SHARES OUTSTANDING

65.881 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

04-15-2025

BETA

1.69

PUBLIC FLOAT

AVERAGE 10 VOLUME

$208,217

AVERAGE 30 VOLUME

$234,522

Company detail

CEO: Mai-Britt Zocca
Region: US
Website: iobiotech.com
Employees: 30
IPO year: 2021

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1)

IOBT - IO Biotech, Inc.